tradingkey.logo
Markets
News
Analysis
Tools
Learn
Stock Score
Stock Score
English
繁体中文
ไทย
Tiếng việt
简体中文
Español
Português
Deutsch
한국어
日本語
tradingkey.logo

Pfizer Inc

PFE
View Detailed Chart
24.289USD
+0.059+0.24%
Market hours （ET）Quotes delayed by 15 min
138.08BMarket Cap
12.84P/E TTM

Pfizer Inc

24.289
+0.059+0.24%
OverviewCompanyFinancialsAnalysis

Overview

Company

Financials

Analysis

Intraday
1m
30m
1h
D
W
M
D

Today

+0.24%

5 Days

-3.77%

1 Month

+1.63%

6 Months

+10.20%

Year to Date

-8.45%

1 Year

-18.14%

View Detailed Chart

TradingKey Stock Score of Pfizer Inc

Currency: USD Updated: 2025-10-16

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Pfizer Inc's Score

Industry at a Glance

Industry Ranking
59 / 173
Overall Ranking
162 / 4692
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 26 analysts
Buy
Current Rating
29.205
Target Price
+19.74%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Pfizer Inc Highlights

StrengthsRisks
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 119.41%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 119.41%.
Fairly Valued
The company’s latest PE is 12.79, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 3.82B shares, decreasing 2.57% quarter-over-quarter.
Held by Irving Kahn
Star Investor Irving Kahn holds 730.99K shares of this stock.

News

[Reuters Breakingviews] Obesity kings’ buffet is slimmer than it looks

Obesity kings’ plump future is under siege. Over the past month Roche ROG.S and Pfizer PFE.N have splurged over $10 billion scooping up promising treatments and other rivals are rapidly developing their own medicines. Incumbents $242 billion Novo Nordisk NOVOb.CO and $722 billion Eli Lilly LLY.N may

ReutersThu, Oct 2
Obesity kings’ plump future is under siege. Over the past month Roche ROG.S and Pfizer PFE.N have splurged over $10 billion scooping up promising treatments and other rivals are rapidly developing their own medicines. Incumbents $242 billion Novo Nordisk NOVOb.CO and $722 billion Eli Lilly LLY.N may

Why BioNTech Stock Jumped by Nearly 4% on Wednesday

Key PointsThe biotech continues to embrace artificial intelligence (AI) technology, which is heartening for investors.It owns and manages an AI developer, InstaDeep.10 stocks we like better than BioNTech Se › Germany-based BioNTech (NASDAQ: BNTX) saw its U.S. listed stock enjoy a mini-pop on Wednesd

The Motley FoolThu, Oct 2
Key PointsThe biotech continues to embrace artificial intelligence (AI) technology, which is heartening for investors.It owns and manages an AI developer, InstaDeep.10 stocks we like better than BioNTech Se › Germany-based BioNTech (NASDAQ: BNTX) saw its U.S. listed stock enjoy a mini-pop on Wednesd

Trump Strikes First Drug Deal: Pfizer Cuts Prices in Exchange for Tariff Relief

TradingKey - On Tuesday, U.S. President Donald Trump announced an agreement with Pfizer under which the pharmaceutical giant will voluntarily slash prices for its drugs in the U.S. market.

TradingKeyWed, Oct 1
TradingKey - On Tuesday, U.S. President Donald Trump announced an agreement with Pfizer under which the pharmaceutical giant will voluntarily slash prices for its drugs in the U.S. market.

Trump executive order demands pharma industry price cuts

WASHINGTON, May 12 (Reuters) - U.S. President Donald Trump signed a wide-reaching executive order on Monday directing drugmakers to lower the prices of their medicines to align with what other countries pay that analysts and legal experts said would be difficult to implement.

ReutersTue, May 13
WASHINGTON, May 12 (Reuters) - U.S. President Donald Trump signed a wide-reaching executive order on Monday directing drugmakers to lower the prices of their medicines to align with what other countries pay that analysts and legal experts said would be difficult to implement.

Trump Plans Major Drug Price Cuts, Pharma Stocks Tumbles

Trump signals an executive order to slash drug prices, causing a sharp sell-off in Asian pharmaceutical stocks. Major companies like Johnson & Johnson, Pfizer, and Abbott could be hit hard.  

TradingKeyMon, May 12
Trump signals an executive order to slash drug prices, causing a sharp sell-off in Asian pharmaceutical stocks. Major companies like Johnson & Johnson, Pfizer, and Abbott could be hit hard.  

The Strategic Repositioning Driving Pfizer's Growth Story

TradingKey - Pfizer’s non-COVID portfolio grew 12% in 2024, led by a 65% surge in Vyndaqel sales and 26% oncology revenue growth.

TradingKeyTue, Apr 8
TradingKey - Pfizer’s non-COVID portfolio grew 12% in 2024, led by a 65% surge in Vyndaqel sales and 26% oncology revenue growth.

Financial Indicators

EPS

No Data

Total revenue

No Data

Pfizer Inc Info

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.
Ticker SymbolPFE
CompanyPfizer Inc
CEODr. Albert Bourla, Ph.D.
Websitehttps://www.pfizer.com/

Related Instruments

LLY
Eli Lilly and Co
-2.40%
JNJ
Johnson & Johnson
-0.07%
ABBV
AbbVie Inc
+1.00%
NVS
Novartis AG
+0.25%
MRK
Merck & Co Inc
-0.27%
NVO
Novo Nordisk A/S
-3.76%
AMGN
Amgen Inc
-0.27%
GILD
Gilead Sciences Inc
+2.55%
SNY
Sanofi SA
+0.80%
VRTX
Vertex Pharmaceuticals Inc
+0.99%
MCK
Mckesson Corp
+0.66%
GSK
GSK plc
-0.35%
BMY
Bristol-Myers Squibb Co
-0.37%
HLN
Haleon PLC
+1.89%
VRNA
Verona Pharma PLC
0.00%
ALNY
Alnylam Pharmaceuticals Inc
+1.40%
ZTS
Zoetis Inc
-0.08%
REGN
Regeneron Pharmaceuticals Inc
+0.36%
CAH
Cardinal Health Inc
-0.44%
TEVA
Teva Pharmaceutical Industries Ltd
-1.46%

Popular Symbols

Bitcoin is a kind of encrypted currency based on decentralization, adopting peer-to-peer network and consensus initiative, open source code, and blockchain as the underlying technology.
Bitcoin
104788.47
-3019.54 (-2.80%)
Ethereum is a decentralized open source public blockchain platform with smart contract functions. As of August 2021, Ethereum is the second-highest cryptocurrency by market value and is the most used blockchain.
Ethereum
3731.01
-117.48 (-3.05%)
Gold denominated in US dollars
Gold
4239.02
-89.06 (-2.06%)
US Crude Oil
WTI
56.926
+0.096 (+0.17%)
Euro vs US Dollar
EUR/USD
1.16656
-0.00210 (-0.18%)
US Dollar vs Japanese Yen
USD/JPY
150.553
+0.131 (+0.09%)
Silver denominated in US dollars
Silver
52.122
-1.917 (-3.55%)
Australian Dollar vs US Dollar
AUD/USD
0.64764
-0.00074 (-0.11%)
Great Britain Pound vs US Dollar
GBP/USD
1.34023
-0.00299 (-0.22%)
Bitcoin Cash (BCH) is both a digital cryptocurrency and a payment network. Bitcoin Cash appeared in December 2017 as a result of Bitcoin's hard fork, with the goal of increasing the number of trades that can be processed.
Bitcoin Cash
455.40
-47.20 (-9.39%)
KeyAI